VT6 Stock Overview A biotechnology company, focuses on the treatment of gene therapy and neurology diseases. More details
Rewards Risk Analysis See All Risk Checks Capture your thoughts, links and company narrative
Voyager Therapeutics, Inc. Competitors Price History & Performance
Summary of share price highs, lows and changes for Voyager Therapeutics Historical stock prices Current Share Price US$5.71 52 Week High US$10.10 52 Week Low US$5.01 Beta 0.90 1 Month Change -9.51% 3 Month Change 5.94% 1 Year Change -42.03% 3 Year Change 130.99% 5 Year Change -53.20% Change since IPO -68.92%
Recent News & Updates
Voyager Therapeutics, Inc. Selects Tau Silencing Gene Therapy Development Candidate for Alzheimer’s Disease and Anticipates Filing an Investigational New Drug Application with the U.S. Food and Drug Administration and Clinical Trial Application with Health Canada for VY1706 in 2026 Nov 21
Third quarter 2024 earnings released: US$0.16 loss per share (vs US$0.59 loss in 3Q 2023) Nov 13
Voyager Therapeutics, Inc. to Report Q3, 2024 Results on Nov 12, 2024 Nov 05
Investor sentiment deteriorates as stock falls 22% Oct 24
Investor sentiment improves as stock rises 23% Oct 08
Investor sentiment deteriorates as stock falls 23% Aug 14 See more updates
Voyager Therapeutics, Inc. Selects Tau Silencing Gene Therapy Development Candidate for Alzheimer’s Disease and Anticipates Filing an Investigational New Drug Application with the U.S. Food and Drug Administration and Clinical Trial Application with Health Canada for VY1706 in 2026 Nov 21
Third quarter 2024 earnings released: US$0.16 loss per share (vs US$0.59 loss in 3Q 2023) Nov 13
Voyager Therapeutics, Inc. to Report Q3, 2024 Results on Nov 12, 2024 Nov 05
Investor sentiment deteriorates as stock falls 22% Oct 24
Investor sentiment improves as stock rises 23% Oct 08
Investor sentiment deteriorates as stock falls 23% Aug 14
Second quarter 2024 earnings released: US$0.18 loss per share (vs US$0.51 loss in 2Q 2023) Aug 07
Voyager Therapeutics, Inc. to Report Q2, 2024 Results on Aug 06, 2024 Jul 30
Voyager Therapeutics, Inc.(NasdaqGS:VYGR) dropped from Russell 2500 Growth Index Jul 03
Voyager Therapeutics, Inc. Appoints Nathan Jorgensen as Chief Financial Officer, Effective July 8, 2024 Jun 15
Voyager Therapeutics, Inc Announces First Participants Dosed in Single Ascending Dose Trial of VY-TAU01 for the Treatment of Alzheimer’s Disease May 18
First quarter 2024 earnings released: US$0.20 loss per share (vs US$3.05 profit in 1Q 2023) May 14
Voyager Therapeutics, Inc. Presents Data for Second-Generation, TRACER™?-Generated Capsids and CNS Gene Therapy Programs Advancing Toward Clinical Trials At the Asgct 27th Annual Meeting May 09
Voyager Therapeutics, Inc. to Report Q1, 2024 Results on May 13, 2024 May 08
Investor sentiment improves as stock rises 16% May 04
Voyager Therapeutics, Inc., Annual General Meeting, Jun 05, 2024 Apr 28
President recently sold €111k worth of stock Apr 05
Investor sentiment improves as stock rises 17% Apr 02
Voyager Therapeutics, Inc. Announces Appointment of Toby Ferguson as Chief Medical Officer, Effective March 25, 2024 Mar 15
Voyager Therapeutics, Inc. Announces Appointment of Toby Ferguson as Chief Medical Officer, Effective March 25, 2024 Mar 13
Full year 2023 earnings released: EPS: US$3.08 (vs US$1.21 loss in FY 2022) Feb 29
Investor sentiment improves as stock rises 27% Feb 29
Voyager Therapeutics, Inc. Announces Selection of Gene Therapy Development Candidate for Friedreich's Ataxia in Collaboration with Neurocrine Biosciences, Triggering Milestone Payment Feb 28
President recently sold €90k worth of stock Feb 27
Voyager Therapeutics, Inc. to Report Q4, 2023 Results on Feb 28, 2024 Feb 22
Voyager Therapeutics Reports Robust Preclinical Activity in Tau Silencing Gene Therapy Program for Alzheimer's Disease and Advances Program into Late Research Feb 20
New major risk - Shareholder dilution Jan 09
Voyager Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $100 million. Jan 06 Voyager Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $100 million.
Investor sentiment improves as stock rises 26% Jan 02
Voyager Therapeutics, Inc. Announces Selection of Development Candidate for SOD1 Amyotrophic Lateral Sclerosis Gene Therapy Program Dec 06
Third quarter 2023 earnings released: US$0.59 loss per share (vs US$0.46 profit in 3Q 2022) Nov 07
Voyager Therapeutics, Inc. to Report Q3, 2023 Results on Nov 06, 2023 Oct 31
Chief Financial Officer recently sold €91k worth of stock Oct 06
Second quarter 2023 earnings released: US$0.51 loss per share (vs US$0.50 loss in 2Q 2022) Aug 04
Voyager Therapeutics, Inc. to Report Q2, 2023 Results on Aug 03, 2023 Jul 29
Investor sentiment deteriorates as stock falls 16% Jul 13
Voyager Therapeutics Announces Appointment of Jacquelyn Fahey Sandell as Chief Legal Officer Jul 11
Investor sentiment improves as stock rises 16% Jun 12
Investor sentiment improves as stock rises 19% May 18
Voyager Therapeutics, Inc. Appoints George Scangos as Director and as Member of Science and Technology Committee May 10
First quarter 2023 earnings released: EPS: US$3.05 (vs US$0.56 loss in 1Q 2022) May 10
President recently sold €54k worth of stock Apr 09
Chief Operating Officer recently sold €120k worth of stock Mar 22
Full year 2022 earnings released: US$1.21 loss per share (vs US$1.89 loss in FY 2021) Mar 09
Voyager Therapeutics, Inc. Appoints Grace E. Colón, Ph.D., to Its Board of Directors, Effective on January 1, 2023 Dec 15
Third quarter 2022 earnings released: EPS: US$0.46 (vs US$0.67 loss in 3Q 2021) Nov 09
Voyager Therapeutics, Inc. to Report Q3, 2022 Results on Nov 08, 2022 Nov 02
Voyager Therapeutics, Inc Presents Data Characterizing a Novel CNS Receptor and Demonstrating the Low-Dose Potential of TRACER™ Generated Capsid Families Oct 12 Voyager Therapeutics Appoints Peter Pfreundschuh as CFO, Effective September 19, 2022
Second quarter 2022 earnings released: US$0.50 loss per share (vs US$0.80 loss in 2Q 2021) Aug 06 Voyager Therapeutics Presents New Data Demonstrating Novel Candidate Therapeutic Antibodies Reduced Tau Pathology in Multiple Preclinical Models Aug 04
Voyager Therapeutics, Inc. to Report Q2, 2022 Results on Aug 04, 2022 Aug 03
Voyager Therapeutics Appoints Catherine J. Mackey, Ph.D. to Its Board of Directors Jul 29
Voyager Therapeutics, Inc. Announces Executive Changes Jun 09
Voyager Therapeutics, Inc. to Present New Preclinical Data on Family of AAV9-Derived Tracer Capsids Demonstrating Cross-Species Central Nervous System (CNS) Transduction May 20
Voyager Therapeutics, Inc. to Present Preclinical Data from Its Vectorized Anti-Her2 Antibody Program and A Novel Aav5-Derived Tracer™ Capsid At the 25Th American Society of Gene and Cell Therapy Annual Meeting May 18
First quarter 2022 earnings released: US$0.56 loss per share (vs US$0.58 loss in 1Q 2021) May 06
Voyager Therapeutics, Inc., Annual General Meeting, Jun 06, 2022 Apr 22
Mark Levin and Steven Paul Requests Voyager Therapeutics Not to Nominate for Re-Election to the Board Apr 21
Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat Mar 09
Voyager Therapeutics, Inc. Announces Executive Appointments Feb 04
Third quarter 2021 earnings released: US$0.67 loss per share (vs US$2.30 profit in 3Q 2020) Nov 03
Investor sentiment deteriorated over the past week Oct 27
Investor sentiment improved over the past week Oct 07
Investor sentiment improved over the past week Sep 06
Investor sentiment deteriorated over the past week Aug 17
Second quarter 2021 earnings released: US$0.80 loss per share (vs US$0.23 loss in 2Q 2020) Aug 10 Voyager Therapeutics, Inc.(NasdaqGS:VYGR) dropped from Russell 3000E Index
Voyager Therapeutics’ Novel Capsids Demonstrate Robust Delivery Across the Blood Brain Barrier, Widespread CNS Transduction in Non-Human Primates May 12
First quarter 2021 earnings released: US$0.58 loss per share (vs US$0.66 loss in 1Q 2020) May 11
Voyager Therapeutics Receives FDA Clearance of IND Application for Gene Therapy Candidate VY-HTT01 for Treatment of Huntington’s Disease Apr 27
Investor sentiment improved over the past week Apr 26
Full year 2020 earnings released: EPS US$0.99 (vs US$1.21 loss in FY 2019) Feb 28
Revenue misses expectations Feb 28
The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Voyager Therapeutics, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm Feb 26
New 90-day low: €5.30 Feb 20
Voyager Therapeutics, Inc. to Report Q4, 2020 Results on Feb 25, 2021 Feb 19
Zhang Investor Law Alerts Investors of Deadline in Securities Class Action Lawsuit Against Voyager Therapeutics, Inc Feb 17
Neurocrine Biosciences, Inc. Enters into Partial Termination of the Collaboration and License Agreement with Voyager Therapeutics, Inc Feb 03
Pomerantz Law Firm Announces the Filing of Class Action Against Voyager Therapeutics, Inc Jan 24
Wendy Dixon Decides to Resign from the Board and All Committees of Voyager Therapeutics, Inc Jan 16
Investor sentiment improved over the past week Jan 09
New 90-day low: €6.00 Dec 30
Investor sentiment deteriorated over the past week Dec 29
New 90-day low: €6.45 Dec 11
Market pulls back on stock over the past week Nov 16
Third quarter 2020 earnings released: EPS US$2.30 Nov 11
New 90-day low: €7.50 Nov 11 Shareholder Returns VT6 DE Biotechs DE Market 7D 5.7% 4.0% 0.7% 1Y -42.0% -10.2% 8.4%
See full shareholder returns
Return vs Market: VT6 underperformed the German Market which returned 8.4% over the past year.
Price Volatility Is VT6's price volatile compared to industry and market? VT6 volatility VT6 Average Weekly Movement 14.2% Biotechs Industry Average Movement 7.3% Market Average Movement 4.9% 10% most volatile stocks in DE Market 12.0% 10% least volatile stocks in DE Market 2.4%
Stable Share Price: VT6's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: VT6's weekly volatility (14%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company Voyager Therapeutics, Inc., a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company’s lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer’s disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer’s disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer’s disease and is in preclinical trial.
Show more Voyager Therapeutics, Inc. Fundamentals Summary How do Voyager Therapeutics's earnings and revenue compare to its market cap? VT6 fundamental statistics Market cap €301.80m Earnings (TTM ) €25.22m Revenue (TTM ) €159.59m
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) VT6 income statement (TTM ) Revenue US$163.78m Cost of Revenue US$117.54m Gross Profit US$46.24m Other Expenses US$20.36m Earnings US$25.88m
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2025/01/02 18:54 End of Day Share Price 2025/01/02 00:00 Earnings 2024/09/30 Annual Earnings 2023/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources Voyager Therapeutics, Inc. is covered by 25 analysts. 11 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Brian Skorney Baird Jack Allen Baird Aydin Huseynov Benchmark Company
Show 22 more analysts 
